Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 169

1.

Detection of post-vaccination enhanced dengue virus infection in macaques: An improved model for early assessment of dengue vaccines.

Borges MB, Marchevsky RS, Carvalho Pereira R, da Silva Mendes Y, Almeida Mendes LG, Diniz-Mendes L, Cruz MA, Tahmaoui O, Baudart S, Freire M, Homma A, Schneider-Ohrum K, Vaughn DW, Vanloubbeeck Y, Lorin C, Malice MP, Caride E, Warter L.

PLoS Pathog. 2019 Apr 22;15(4):e1007721. doi: 10.1371/journal.ppat.1007721. eCollection 2019 Apr.

2.

Evaluation of a primary course of H9N2 vaccine with or without AS03 adjuvant in adults: A phase I/II randomized trial.

Madan A, Collins H, Sheldon E, Frenette L, Chu L, Friel D, Drame M, Vaughn DW, Innis BL, Schuind A.

Vaccine. 2017 Aug 16;35(35 Pt B):4621-4628. doi: 10.1016/j.vaccine.2017.07.013. Epub 2017 Jul 15.

3.

Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials.

van der Most RG, Clément F, Willekens J, Dewé W, Walravens K, Vaughn DW, Leroux-Roels G.

Clin Vaccine Immunol. 2017 Jun 5;24(6). pii: e00553-16. doi: 10.1128/CVI.00553-16. Print 2017 Jun.

4.

Respiratory viruses and influenza-like illness: Epidemiology and outcomes in children aged 6 months to 10 years in a multi-country population sample.

Taylor S, Lopez P, Weckx L, Borja-Tabora C, Ulloa-Gutierrez R, Lazcano-Ponce E, Kerdpanich A, Angel Rodriguez Weber M, Mascareñas de Los Santos A, Tinoco JC, Safadi MA, Lim FS, Hernandez-de Mezerville M, Faingezicht I, Cruz-Valdez A, Feng Y, Li P, Durviaux S, Haars G, Roy-Ghanta S, Vaughn DW, Nolan T.

J Infect. 2017 Jan;74(1):29-41. doi: 10.1016/j.jinf.2016.09.003. Epub 2016 Sep 22.

PMID:
27667752
5.

Dengue Virus (DENV) Neutralizing Antibody Kinetics in Children After Symptomatic Primary and Postprimary DENV Infection.

Clapham HE, Rodriguez-Barraquer I, Azman AS, Althouse BM, Salje H, Gibbons RV, Rothman AL, Jarman RG, Nisalak A, Thaisomboonsuk B, Kalayanarooj S, Nimmannitya S, Vaughn DW, Green S, Yoon IK, Cummings DA.

J Infect Dis. 2016 May 1;213(9):1428-35. doi: 10.1093/infdis/jiv759. Epub 2015 Dec 23.

6.

Assessment of Prime-boost Vaccination Using an AS03B-adjuvanted Influenza A (H5N1) Vaccine: A Randomized Trial in Children of Three to Less Than Eighteen Years of Age.

Izurieta P, Uy-Aragon MJ, Dramé M, Vaughn DW.

Pediatr Infect Dis J. 2016 Feb;35(2):e35-47. doi: 10.1097/INF.0000000000000968.

PMID:
26551446
7.

Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine in Children 6 Months to 17 Years of Age, Previously Vaccinated with an AS03-Adjuvanted A(H1N1)Pdm09 Vaccine: Two Open-label, Randomized Trials.

Vesikari T, Richardus JH, Berglund J, Korhonen T, Flodmark CE, Lindstrand A, Silfverdal SA, Bambure V, Caplanusi A, Dieussaert I, Roy-Ghanta S, Vaughn DW.

Pediatr Infect Dis J. 2015 Jul;34(7):774-82. doi: 10.1097/INF.0000000000000709.

PMID:
26069949
8.

Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: a phase IV, randomized, open-label, controlled study.

Izurieta P, Kim WJ, Wie SH, Lee J, Lee JS, Dramé M, Vaughn DW, Schuind A.

Vaccine. 2015 Jun 4;33(24):2800-7. doi: 10.1016/j.vaccine.2015.04.027. Epub 2015 Apr 21.

9.

Prevalence and Incidence of Respiratory Syncytial Virus and Other Respiratory Viral Infections in Children Aged 6 Months to 10 Years With Influenza-like Illness Enrolled in a Randomized Trial.

Nolan T, Borja-Tabora C, Lopez P, Weckx L, Ulloa-Gutierrez R, Lazcano-Ponce E, Kerdpanich A, Weber MA, Mascareñas de Los Santos A, Tinoco JC, Safadi MA, Seng LF, Hernandez-de Mezerville M, Faingezicht I, Cruz-Valdez A, Feng Y, Li P, Durviaux S, Haars G, Roy-Ghanta S, Vaughn DW, Taylor S.

Clin Infect Dis. 2015 Jun 1;60(11):e80-9. doi: 10.1093/cid/civ065. Epub 2015 Feb 11.

10.

Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: pooled analysis of 28 clinical trials.

Vaughn DW, Seifert H, Hepburn A, Dewe W, Li P, Drame M, Cohet C, Innis BL, Fries LF.

Hum Vaccin Immunother. 2014;10(10):2942-57. doi: 10.4161/21645515.2014.972149. Epub 2014 Nov 21.

11.

Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: a randomized controlled clinical trial.

Langley JM, Frenette L, Jeanfreau R, Halperin SA, Kyle M, Chu L, McNeil S, Dramé M, Moris P, Fries L, Vaughn DW.

Vaccine. 2015 Jan 15;33(4):559-67. doi: 10.1016/j.vaccine.2014.11.018. Epub 2014 Nov 21.

12.

AS03B-adjuvanted H5N1 influenza vaccine in children 6 months through 17 years of age: a phase 2/3 randomized, placebo-controlled, observer-blinded trial.

Kosalaraksa P, Jeanfreau R, Frenette L, Drame M, Madariaga M, Innis BL, Godeaux O, Izurieta P, Vaughn DW.

J Infect Dis. 2015 Mar 1;211(5):801-10. doi: 10.1093/infdis/jiu548. Epub 2014 Oct 6.

13.

Seeking help: B cells adapting to flu variability.

van der Most RG, Roman FP, Innis B, Hanon E, Vaughn DW, Gillard P, Walravens K, Wettendorff M.

Sci Transl Med. 2014 Jul 23;6(246):246ps8. doi: 10.1126/scitranslmed.3008409.

PMID:
25101885
14.

Immunogenicity and safety of AS03A-adjuvanted H5N1 influenza vaccine prepared from bulk antigen after stockpiling for 4 years.

Godeaux O, Izurieta P, Madariaga M, Dramé M, Li P, Vaughn DW.

Vaccine. 2015 Apr 27;33(18):2189-95. doi: 10.1016/j.vaccine.2014.07.062. Epub 2014 Jul 30.

15.

Heterologous prime-boost vaccination using an AS03B-adjuvanted influenza A(H5N1) vaccine in infants and children<3 years of age.

Nolan T, Izurieta P, Lee BW, Chan PC, Marshall H, Booy R, Drame M, Vaughn DW.

J Infect Dis. 2014 Dec 1;210(11):1800-10. doi: 10.1093/infdis/jiu359. Epub 2014 Jun 27.

16.

Responses to A(H1N1)pdm09 influenza vaccines in participants previously vaccinated with seasonal influenza vaccine: a randomized, observer-blind, controlled study.

Roy-Ghanta S, Van der Most R, Li P, Vaughn DW.

J Infect Dis. 2014 Nov 1;210(9):1419-30. doi: 10.1093/infdis/jiu284. Epub 2014 May 26.

17.

Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trial.

Nolan T, Roy-Ghanta S, Montellano M, Weckx L, Ulloa-Gutierrez R, Lazcano-Ponce E, Kerdpanich A, Safadi MA, Cruz-Valdez A, Litao S, Lim FS, de Los Santos AM, Weber MA, Tinoco JC, Mezerville MH, Faingezicht I, Kosuwon P, Lopez P, Borja-Tabora C, Li P, Durviaux S, Fries L, Dubin G, Breuer T, Innis BL, Vaughn DW.

J Infect Dis. 2014 Aug 15;210(4):545-57. doi: 10.1093/infdis/jiu173. Epub 2014 Mar 20.

18.

Evaluation of dengue virus strains for human challenge studies.

Mammen MP, Lyons A, Innis BL, Sun W, McKinney D, Chung RC, Eckels KH, Putnak R, Kanesa-thasan N, Scherer JM, Statler J, Asher LV, Thomas SJ, Vaughn DW.

Vaccine. 2014 Mar 14;32(13):1488-94. doi: 10.1016/j.vaccine.2013.12.040. Epub 2014 Jan 24.

PMID:
24468542
19.

A phased rehabilitation protocol for athletes with lumbar intervertebral disc herniation.

Vangelder LH, Hoogenboom BJ, Vaughn DW.

Int J Sports Phys Ther. 2013 Aug;8(4):482-516.

20.

Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials.

Launay O, Duval X, Fitoussi S, Jilg W, Kerdpanich A, Montellano M, Schwarz TF, Watanveerade V, Wenzel JJ, Zalcman G, Bambure V, Li P, Caplanusi A, Madan A, Gillard P, Vaughn DW.

BMC Infect Dis. 2013 Sep 16;13:435. doi: 10.1186/1471-2334-13-435.

21.

A model international partnership for community-based research on vaccine-preventable diseases: the Kamphaeng Phet-AFRIMS Virology Research Unit (KAVRU).

Gibbons RV, Nisalak A, Yoon IK, Tannitisupawong D, Rungsimunpaiboon K, Vaughn DW, Endy TP, Innis BL, Burke DS, Mammen MP Jr, Scott RM, Thomas SJ, Hoke CH Jr.

Vaccine. 2013 Sep 23;31(41):4487-500. doi: 10.1016/j.vaccine.2013.07.082. Epub 2013 Aug 8. Review.

PMID:
23933334
22.

Spinal manual therapy interventions for pediatric patients: a systematic review.

Vaughn DW, Kenyon LK, Sobeck CM, Smith RE.

J Man Manip Ther. 2012 Aug;20(3):153-9. doi: 10.1179/2042618612Y.0000000007.

23.

Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial.

Yang WH, Dionne M, Kyle M, Aggarwal N, Li P, Madariaga M, Godeaux O, Vaughn DW.

Vaccine. 2013 Sep 13;31(40):4389-97. doi: 10.1016/j.vaccine.2013.07.007. Epub 2013 Jul 12.

25.

Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines.

Sun W, Eckels KH, Putnak JR, Lyons AG, Thomas SJ, Vaughn DW, Gibbons RV, Fernandez S, Gunther VJ, Mammen MP Jr, Statler JD, Innis BL.

J Infect Dis. 2013 Mar 1;207(5):700-8. doi: 10.1093/infdis/jis744. Epub 2012 Dec 5.

PMID:
23225894
26.

Clinical trial registration in physiotherapy journals: recommendations from the International Society of Physiotherapy Journal Editors.

Costa LO, Lin CW, Grossi DB, Mancini MC, Swisher AK, Cook CE, Vaughn DW, Elkins MR, Sheikh U, Moore A, Jull GA, Craik RL, Maher CG, Guirro RR, Marques AP, Harms M, Brooks D, Simoneau GG, Strupstad JH.

J Orthop Sports Phys Ther. 2012 Dec;42(12):978-81. doi: 10.2519/jospt.2012.0111. Epub 2012 Nov 30.

PMID:
23201914
27.

US Military contributions to the global response to pandemic chikungunya.

Hoke CH Jr, Pace-Templeton J, Pittman P, Malinoski FJ, Gibbs P, Ulderich T, Mathers M, Fogtman B, Glass P, Vaughn DW.

Vaccine. 2012 Oct 19;30(47):6713-20. doi: 10.1016/j.vaccine.2012.08.025. Epub 2012 Aug 29.

PMID:
22940380
28.

Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity.

Langley JM, Reich D, Aggarwal N, Connor D, Lebel MH, Gupta A, Garfield H, Li P, Madan A, Vaughn DW.

Pediatr Infect Dis J. 2012 Aug;31(8):848-58. doi: 10.1097/INF.0b013e31825e6cd6.

PMID:
22801094
29.

Safety and persistence of immunological response 6 months after intramuscular vaccination with an AS03-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized trial in Japanese children aged 6 months to 17 years.

Saitoh A, Nagai A, Tenjinbaru K, Li P, Vaughn DW, Roman F, Kato T.

Hum Vaccin Immunother. 2012 Jun;8(6):749-58. doi: 10.4161/hv.19684. Epub 2012 Apr 12.

PMID:
22495117
30.

Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion.

Garçon N, Vaughn DW, Didierlaurent AM.

Expert Rev Vaccines. 2012 Mar;11(3):349-66. doi: 10.1586/erv.11.192. Review.

PMID:
22380826
31.

Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants.

Watanaveeradej V, Simasathien S, Nisalak A, Endy TP, Jarman RG, Innis BL, Thomas SJ, Gibbons RV, Hengprasert S, Samakoses R, Kerdpanich A, Vaughn DW, Putnak JR, Eckels KH, Barrera Rde L, Mammen MP Jr.

Am J Trop Med Hyg. 2011 Aug;85(2):341-51. doi: 10.4269/ajtmh.2011.10-0501.

32.
33.

Dengue hemorrhagic fever: the sensitivity and specificity of the world health organization definition for identification of severe cases of dengue in Thailand, 1994-2005.

Srikiatkhachorn A, Gibbons RV, Green S, Libraty DH, Thomas SJ, Endy TP, Vaughn DW, Nisalak A, Ennis FA, Rothman AL, Nimmannitaya S, Kalayanarooj S.

Clin Infect Dis. 2010 Apr 15;50(8):1135-43. doi: 10.1086/651268.

34.

Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: How alterations in assay conditions impact performance.

Thomas SJ, Nisalak A, Anderson KB, Libraty DH, Kalayanarooj S, Vaughn DW, Putnak R, Gibbons RV, Jarman R, Endy TP.

Am J Trop Med Hyg. 2009 Nov;81(5):825-33. doi: 10.4269/ajtmh.2009.08-0625.

35.

TNF and LTA gene, allele, and extended HLA haplotype associations with severe dengue virus infection in ethnic Thais.

Vejbaesya S, Luangtrakool P, Luangtrakool K, Kalayanarooj S, Vaughn DW, Endy TP, Mammen MP, Green S, Libraty DH, Ennis FA, Rothman AL, Stephens HA.

J Infect Dis. 2009 May 15;199(10):1442-8. doi: 10.1086/597422.

36.

Isolated knee pain: a case report highlighting regional interdependence.

Vaughn DW.

J Orthop Sports Phys Ther. 2008 Oct;38(10):616-23. doi: 10.2519/jospt.2008.2759.

PMID:
18827328
37.

Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults.

Sun W, Cunningham D, Wasserman SS, Perry J, Putnak JR, Eckels KH, Vaughn DW, Thomas SJ, Kanesa-Thasan N, Innis BL, Edelman R.

Hum Vaccin. 2009 Jan-Feb;5(1):33-40. Epub 2009 Jan 27.

PMID:
18670195
38.

Infectious diseases investment decision evaluation algorithm: a quantitative algorithm for prioritization of naturally occurring infectious disease threats to the U.S. military.

Burnette WN, Hoke CH Jr, Scovill J, Clark K, Abrams J, Kitchen LW, Hanson K, Palys TJ, Vaughn DW.

Mil Med. 2008 Feb;173(2):174-81.

PMID:
18333494
39.

A comparative study of leptospirosis and dengue in Thai children.

Libraty DH, Myint KS, Murray CK, Gibbons RV, Mammen MP, Endy TP, Li W, Vaughn DW, Nisalak A, Kalayanarooj S, Hospenthal DR, Green S, Rothman AL, Ennis FA.

PLoS Negl Trop Dis. 2007 Dec 26;1(3):e111.

40.

Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences.

Gibbons RV, Kalanarooj S, Jarman RG, Nisalak A, Vaughn DW, Endy TP, Mammen MP Jr, Srikiatkhachorn A.

Am J Trop Med Hyg. 2007 Nov;77(5):910-3.

PMID:
17984352
41.

Role of U.S. military research programs in the development of U.S.-licensed vaccines for naturally occurring infectious diseases.

Kitchen LW, Vaughn DW.

Vaccine. 2007 Oct 10;25(41):7017-30. Epub 2007 Aug 6. Review.

PMID:
17728025
42.

Prospective study to determine accuracy of rapid serological assays for diagnosis of acute dengue virus infection in Laos.

Blacksell SD, Bell D, Kelley J, Mammen MP Jr, Gibbons RV, Jarman RG, Vaughn DW, Jenjaroen K, Nisalak A, Thongpaseuth S, Vongsouvath M, Davong V, Phouminh P, Phetsouvanh R, Day NP, Newton PN.

Clin Vaccine Immunol. 2007 Nov;14(11):1458-64. Epub 2007 Aug 22.

43.

Characterization of monoclonal antibodies to hepatitis E virus (HEV) capsid protein and identification of binding activity.

He J, Kuschner RA, Dewar V, Voet P, Asher LV, Vaughn DW.

J Biomed Sci. 2007 Sep;14(5):555-63. Epub 2007 May 9.

PMID:
17487571
44.

Burden of symptomatic dengue infection in children at primary school in Thailand: a prospective study.

Anderson KB, Chunsuttiwat S, Nisalak A, Mammen MP, Libraty DH, Rothman AL, Green S, Vaughn DW, Ennis FA, Endy TP.

Lancet. 2007 Apr 28;369(9571):1452-1459. doi: 10.1016/S0140-6736(07)60671-0.

PMID:
17467515
45.

Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17-18 November 2005.

Hombach J, Cardosa MJ, Sabchareon A, Vaughn DW, Barrett AD.

Vaccine. 2007 May 22;25(21):4130-9. Epub 2007 Mar 16.

PMID:
17428588
46.

Safety and efficacy of a recombinant hepatitis E vaccine.

Shrestha MP, Scott RM, Joshi DM, Mammen MP Jr, Thapa GB, Thapa N, Myint KS, Fourneau M, Kuschner RA, Shrestha SK, David MP, Seriwatana J, Vaughn DW, Safary A, Endy TP, Innis BL.

N Engl J Med. 2007 Mar 1;356(9):895-903.

47.

The study transplacental chikungunya virus antibody kinetics, Thailand.

Watanaveeradej V, Endy TP, Simasathien S, Kerdpanich A, Polprasert N, Aree C, Vaughn DW, Nisalak A.

Emerg Infect Dis. 2006 Nov;12(11):1770-2.

48.

A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis.

Lyons A, Kanesa-thasan N, Kuschner RA, Eckels KH, Putnak R, Sun W, Burge R, Towle AC, Wilson P, Tauber E, Vaughn DW.

Vaccine. 2007 Apr 30;25(17):3445-53. Epub 2007 Jan 4.

PMID:
17241714
50.

Cellular immune activation in children with acute dengue virus infections is modulated by apoptosis.

Myint KS, Endy TP, Mongkolsirichaikul D, Manomuth C, Kalayanarooj S, Vaughn DW, Nisalak A, Green S, Rothman AL, Ennis FA, Libraty DH.

J Infect Dis. 2006 Sep 1;194(5):600-7. Epub 2006 Jul 31.

PMID:
16897658

Supplemental Content

Loading ...
Support Center